Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study of NT-Pro-Brain Peptide (NT-proBNP) in Patients Scheduled for Major Vascular Surgery.

Status: Recruiting

Protocol number: DECREASE-VI

Company division: Diagnostic

Official Scientific Title: A prospective study to assess the screening value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for the identification of patients that benefit from additional cardiac testing prior to vascular surgery.

Brief summary: The purpose of this study is to validate the screening potential of NT-proBNP for the identification of patients scheduled for vascular surgery who would benefit from additional pre-operative cardiac testing. All patients will have NT-proBNP concentrations measured pre-operatively. For low-intermediate risk patients only those with abnormal values will receive further cardiac testing; all high risk patients will be referred for additional testing.

Study type: Interventional; Non-Randomized; Open Label; Historical; Parallel study

Condition: Peripheral Vascular Disease

Intervention type: Diagnostic Test

Intervention name: ELECSYS®proBNP

Inclusion criteria:

  • adult patients, ≥18 years of age;
  • patients with peripheral vascular atherosclerosis, scheduled for vascular surgery.

Exclusion criteria:

  • N/A.

Gender: Males or Females

Age limits: Min: 18 Years Max: N/A (No limit)

Accepts healthy volunteers: No

Anticipated start date: February, 2007

Trial registration date: 08/21/2007

Date last updated: 10/15/2008


Link to trial result

This trial is being conducted at the following locations:

Belgium

  • Gent
  • Leuven

Brazil

  • Sao Paulo

France

  • Besancon

Ireland

  • Dublin

Italy

  • Florence

Netherlands

  • Arnhem
  • Beverwijk
  • Heerlen
  • Hoogeveen
  • Nieuwegein
  • Nijmegen
  • Rotterdam
  • Zwolle

Poland

  • Wroclaw

Serbia and Montenegro

  • Belgrade

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply